Risperidone
FDA-approved product (tablet, oral), marketed as Perseris Kit, Risperdal, Risperdal Consta and 4 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Aggressive behavior
- Autism
- Bipolar disorder
- Bipolar I disorder
- Psychosis
- Schizoaffective disorder
- Schizophrenia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antipsychotics
- FDA pharmacologic class
- Atypical Antipsychotic FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli54.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Risperidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Primaquine PhosphateExisting use: Malaria59.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LypressinExisting use: Vasopressin and analogues59.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- BrexpiprazoleExisting use: Major depressive disorder, Psychosis, Schizoaffective disorder and 1 more59.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Baloxavir MarboxilExisting use: Influenza, Viral disease59.2% AI-predicted activityagainst M. tuberculosis24 registered studies
- Fluvastatin SodiumExisting use: Cardiovascular disease, Familial hypercholesterolemia, Hypercholesterolemia59.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- OndansetronExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 4 more59.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MethyldopaExisting use: Hypertension59.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Asciminib HydrochlorideExisting use: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic myelogenous leukemia, Neoplasm59.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- DofetilideExisting use: Atrial fibrillation, Atrial flutter, Cardiac arrhythmia and 1 more59.0% AI-predicted activityagainst M. tuberculosis22 registered studies
- Fedratinib HydrochlorideExisting use: Myelofibrosis, Myeloproliferative disorder, Neoplasm and 1 more59.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- MetolazoneExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more59.0% AI-predicted activityagainst M. tuberculosis36 registered studies
- Nelfinavir MesylateExisting use: HIV infection, HIV-1 infection59.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
NCT00236457 · start 2000-11
Registered record
- Registry ID
- NCT00236457
- Conditions
- Schizophrenia; Psychotic Disorders
- Interventions
- risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2000-11
- Completion
- 2002-12
- Enrolment
- 629
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia; Psychotic DisordersInterventionrisperidonePhasePhase 3Registry statusCompletedSupported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
NCT00183625 · start 2000-06
Registered record
- Registry ID
- NCT00183625
- Conditions
- Schizophrenia
- Interventions
- Individual Placement and Support (Supported Employment); Social Skills Training; Olanzapine; Risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-06
- Completion
- 2006-09
- Enrolment
- 107
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionIndividual Placement and Support (Supported Employment); Social Skills Training; Olanzapine; RisperidonePhasePhase 4Registry statusCompletedA Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
NCT00253136 · start 1999-11
Registered record
- Registry ID
- NCT00253136
- Conditions
- Schizophrenia; Psychotic Disorders
- Interventions
- risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1999-11
- Completion
- 2000-12
- Enrolment
- 458
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia; Psychotic DisordersInterventionrisperidonePhasePhase 3Registry statusCompletedRisperidone for Treatment of Cocaine Dependence in Outpatients - 12
NCT00000347 · start 1997-07
Registered record
- Registry ID
- NCT00000347
- Conditions
- Cocaine-Related Disorders
- Interventions
- Risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1997-07
- Completion
- 1998-09
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCocaine-Related DisordersInterventionRisperidonePhasePhase 2Registry statusCompletedBioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions
NCT00939926
Registered record
- Registry ID
- NCT00939926
- Conditions
- Healthy
- Interventions
- Risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionRisperidonePhasePhase 1Registry statusCompleted